Affiliation: Queensland Institute of Medical Research
- Peginterferon-alpha 2a for the treatment of hepatitis B infectionW Graham E Cooksley
Royal Brisbane Hospital, University of Queensland, Brisbane 4029, Australia
Expert Opin Pharmacother 6:1373-80. 2005..PEG-IFN-alpha2a could become the treatment of choice in many patients with both HBeAg-positive and HBeAg-negative disease and, in those who fail to respond, consideration could then be given to the use of antiviral agents...
- The importance and benefits of hepatitis A prevention in chronic liver disease patientsGraham Cooksley
Clinical Research Center, Royal Brisbane Hospital, Queensland, Australia
J Gastroenterol Hepatol 19:S17-20. 2004
- Treatment with interferons (including pegylated interferons) in patients with hepatitis BW Graham Cooksley
Department of Medicine, The University of Queensland, Royal Brisbane Hospital, Queensland, Australia
Semin Liver Dis 24:45-53. 2004..Side effects in all studies have been tolerable. Thus, these observations in chronic HBV infection, whether HBeAg-positive or HBeAg-negative, suggest an important, even primary, role for pegylated interferon therapy...
- Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis BW G E Cooksley
Royal Brisbane Hospital, Herston, Queensland, Australia
J Viral Hepat 10:298-305. 2003..These results indicate that peginterferon alpha-2a (40 kDa) is superior in efficacy to conventional interferon alpha-2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT...
- Therapies for viral hepatitis workshop. 2-3 November 2004, Boston, MA, USAGraham Cooksley
Royal Brisbane Hospital Foundation, Clinical Research Centre, H Floor BanCroft Centre, Herston, QLD 4029, Australia
IDrugs 8:124-6. 2005
- Treatment of hepatitis B with interferon and combination therapyW Graham Cooksley
Department of Medicine, The University of Queensland, C8 Clinical Sciences Building, Royal Brisbane Hospital, Queensland 4029, Australia
Clin Liver Dis 8:353-70. 2004..Selecting patients for treatment and knowing when to treat them is as important as knowing which medicine to treat them with...
- Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?Graham Cooksley
University of Queensland, Royal Brisbane Hospital, Brisbane, Australia
Nat Clin Pract Gastroenterol Hepatol 2:12-3. 2005
- The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferonGraham Cooksley
Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Brisbane, QLD, Australia
J Hepatol 39:S143-5. 2003
- The role of interferon therapy in hepatitis BW Graham E Cooksley
Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia
MedGenMed 6:16. 2004
- Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infectionCarolyn A Lang
Center for Diabetes and Endocrine Research, The University of Queensland, Queensland, Australia
J Pain Symptom Manage 31:335-44. 2006..These data demonstrate that symptoms are prevalent in treatment-naïve people with HCV and support the hypothesis that symptom clustering occurs...
- Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo
Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Clin Gastroenterol Hepatol 4:233-48. 2006..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...